Research
Study identifies potential new approach for treating lupus
Jan. 13, 2023—A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.
Antibody “fingerprinting” method potential advance to slow spread of dengue
Jan. 12, 2023—Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.
Chan Zuckerberg Initiative grant supports single-cell study of rare inherited disease
Jan. 12, 2023—A multidisciplinary team led by Vanderbilt University Medical Center investigator Alexander Bick, MD, PhD, has been awarded a $2 million, four-year grant to study inflammation at the single-cell level in the rare disease RUNX1-FPD.
Study may lead to new diabetes, heart disease treatments
Jan. 12, 2023—Vanderbilt research found that deletion of an autophagy-participating factor named PIK3C3 from the fat cells of mice led to compromised body temperature control, abnormal blood lipid levels, fatty liver and diabetes.
Roden honored for his leadership in precision medicine
Jan. 12, 2023—Vanderbilt's Dan Roden, MD, will receive the PMWC 2023 Pioneer Award Jan. 27 during this year’s Precision Medicine World Conference.
Anti-nausea drug response in children
Jan. 10, 2023—Genetic variation in a metabolic enzyme was not associated with response to the anti-nausea drug odansetron in children, Vanderbilt researchers report.
Novel lung cancer biomarker
Jan. 9, 2023—Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer.
Early effects of Huntington disease
Jan. 6, 2023—Impairments in brain executive function happen earlier than motor symptoms in people with the gene mutation that causes Huntington disease, suggesting younger ages and cognitive symptoms be considered for any future clinical trials.
MicroRNAs linked to lipid damage
Jan. 6, 2023—VUMC researchers have linked microRNAs with systemic lipid peroxidation, a discovery that could point to new therapeutic targets for a variety of diseases.
VUMC researchers upend dogma about vasopressin production
Jan. 5, 2023—Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.
Vanderbilt mourns loss of renowned scientist Exton
Dec. 28, 2022—John H. Exton, MBChB, MD, PhD, professor of Molecular Physiology and Biophysics, emeritus at Vanderbilt University, whose research provided fundamental insights into how many biologically active compounds control cellular physiology, died Dec. 18. He was 89.
VUMC Announces VICTR Leadership Transition
Dec. 16, 2022—by Bill Snyder Gordon Bernard, MD, a leader in clinical and translational medicine at Vanderbilt University Medical Center for more than 40 years, will step aside from his institutional leadership roles in July 2023 to focus more on his research interests and allow a new generation of leaders to take center stage. Bernard, the Melinda...